Anjeli Mase

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Multidrug Resistant

Tyrosine Kinase

Chronic Myeloid Leukemia

Top Venues

Open forum infectious diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B Leske, Delphine Rea, Stacey Phan, Kaeli B Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P Jacobson, Neil P Shah
BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib. Blood (2024)
Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B Leske, Delphine Rea, Stacey Phan, Kaeli B Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P Jacobson, Neil P Shah
BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib. Blood (2024)
Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B Leske, Delphine Rea, Stacey Phan, Kaeli B Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P Jacobson, Neil P Shah
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood 144 (6) (2024)
Anjeli Mase, Phil Lowenthal, Lisa True, Leslie Henry, Pennan M Barry, Jennifer Flood
Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis. Open forum infectious diseases 9 (12) (2022)
Anjeli Mase, Phil Lowenthal, Lisa True, Leslie Henry, Pennan M Barry, Jennifer Flood
Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis. Open forum infectious diseases 9 (12) (2022)